Common Oral Antibiotic Regimens
Oral antibiotics should be selected based on the suspected pathogen, infection site, and local resistance patterns, with amoxicillin-clavulanate being a versatile first-line option for many common infections due to its broad spectrum of activity against both gram-positive and gram-negative organisms.
First-Line Oral Antibiotic Options by Infection Type
Skin and Soft Tissue Infections
Impetigo
- Dicloxacillin: 500 mg 4 times daily (adults); 25 mg/kg/day in 4 divided doses (children) 1
- Cephalexin: 500 mg 4 times daily (adults); 25-50 mg/kg/day in 4 divided doses (children) 1
- Clindamycin: 300-400 mg 3 times daily (adults); 10-20 mg/kg/day in 3 divided doses (children) 1
MRSA Infections
- Trimethoprim-sulfamethoxazole: 1-2 double-strength tablets twice daily (adults); 8-12 mg/kg/day (based on trimethoprim) in 2 divided doses (children) 1
- Doxycycline: 100 mg twice daily (adults, not recommended for children <8 years) 1
- Linezolid: 600 mg twice daily (adults); 10 mg/kg every 12 hours (children) 1
Animal/Human Bites
- Amoxicillin-clavulanate: 875/125 mg twice daily (adults); 25 mg/kg/day of amoxicillin component in 2 divided doses (children) 1
Respiratory Tract Infections
Acute Sinusitis
- Amoxicillin-clavulanate: 875/125 mg twice daily (adults) 1
- Cefuroxime-axetil: 500 mg twice daily (adults) 1
- Cefpodoxime-proxetil: Adult dosing typically 200 mg twice daily 1
Community-Acquired Pneumonia (Outpatient)
- Azithromycin: 500 mg on day 1, then 250 mg daily for 4 days (adults) 2
- Amoxicillin-clavulanate: 875/125 mg twice daily for 7 days (adults) 2
Urinary Tract Infections
- Co-trimoxazole (Trimethoprim-sulfamethoxazole): 160/800 mg (1 double-strength tablet) twice daily for 3-5 days 1
- Ciprofloxacin: 250-500 mg twice daily for 3 days 3
- Amoxicillin-clavulanate: 500/125 mg twice daily for 3-7 days (less effective than fluoroquinolones) 3
Special Considerations for Specific Pathogens
Methicillin-Susceptible Staphylococcus aureus (MSSA)
- Dicloxacillin: 500 mg 4 times daily (adults) - oral agent of choice 1
- Cephalexin: 500 mg 4 times daily (adults) 1
Streptococcal Infections
Extended Spectrum Beta-Lactamase (ESBL) Producing Organisms
- Consider combination therapy with third-generation oral cephalosporins and amoxicillin-clavulanate 4
Dosing Considerations
Amoxicillin-Clavulanate Formulations
- Standard adult formulation: 875/125 mg twice daily 4, 5
- High-dose formulation: 2000/125 mg twice daily (for resistant pathogens) 6
- Pediatric formulation: 25-45 mg/kg/day of amoxicillin component in 2 divided doses 1
Azithromycin Regimens
- 3-day regimen: 500 mg daily for 3 days or 1 g once daily for 3 days 7, 2
- 5-day regimen: 500 mg on day 1, then 250 mg daily for 4 days 7
Clinical Pearls and Pitfalls
Antibiotic resistance considerations: Local resistance patterns should guide empiric therapy. For example, high rates of MRSA may necessitate initial coverage with trimethoprim-sulfamethoxazole or doxycycline 1
Pediatric dosing caution: Fluoroquinolones are generally contraindicated in children under 18 years, and tetracyclines should be avoided in children under 8 years 1
Duration of therapy: Most uncomplicated infections require 5-7 days of treatment, though some newer regimens (like azithromycin) may be effective with shorter courses 2
Amoxicillin-clavulanate limitations: Despite its broad spectrum, it has shown inferior efficacy compared to ciprofloxacin for urinary tract infections, even against susceptible strains 3
Gastrointestinal tolerability: Twice-daily formulations of amoxicillin-clavulanate may have improved GI tolerability compared to three-times-daily regimens due to reduced daily clavulanate exposure 5
Weight-based dosing in children: In resource-limited settings where scales may not be available, age-based formulae or tools like the Broselow Tape or Mercy TAPE can help estimate appropriate dosing 1
By selecting the appropriate oral antibiotic regimen based on the suspected pathogen and site of infection, clinicians can optimize treatment outcomes while minimizing adverse effects and the development of antimicrobial resistance.